VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.45%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$243M
AUM Growth
+$6.44M
(+2.7%)
Cap. Flow
-$3.44M
Cap. Flow
% of AUM
-1.41%
Top 10 Holdings %
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11
Top Buys
| 1 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
$670K |
| 2 |
Zai Lab
ZLAB
|
$520K |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$422K |
| 4 |
DRD
DRDGold
DRD
|
$405K |
| 5 |
Stellus Capital Investment Corp
SCM
|
$402K |
Top Sells
| 1 |
AMRS
Amyris Inc.
AMRS
|
$1.28M |
| 2 |
Prothena Corp
PRTA
|
$971K |
| 3 |
BioNTech
BNTX
|
$787K |
| 4 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
$647K |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$645K |
Sector Composition
| 1 | Healthcare | 27.38% |
| 2 | Real Estate | 18.81% |
| 3 | Energy | 13.29% |
| 4 | Materials | 10.7% |
| 5 | Utilities | 10.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Viking Therapeutics
VKTX
$3.03B
| $220K | 0.09% |
36,791
-7,964
| -18% | -$47.6K |
|
277
Q32 Bio
QTTB
$20.4M
| $220K | 0.09% |
1,682
+288
| +21% | +$37.7K |
|
278
Ascendis Pharma
ASND
$12.5B
| $219K | 0.09% |
1,664
+23
| +1% | +$3.03K |
|
279
Phathom Pharmaceuticals
PHAT
$875M
| $219K | 0.09% |
6,476
-277
| -4% | -$9.37K |
|
|
DRNA
280
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $219K | 0.09% |
5,880
-6,272
| -52% | -$234K |
|
281
Compugen
CGEN
$134M
| $218K | 0.09% |
26,285
+3,049
| +13% | +$25.3K |
|
|
CMPS
282
Compass Pathways
CMPS
$493M
| $218K | 0.09% |
+5,724
| New | +$218K |
|
283
Geron
GERN
$893M
| $218K | 0.09% |
154,267
-18,324
| -11% | -$25.9K |
|
284
Mirum Pharmaceuticals
MIRM
$3.82B
| $218K | 0.09% |
12,602
+87
| +0.7% | +$1.51K |
|
285
Fate Therapeutics
FATE
$116M
| $216K | 0.09% |
2,486
-624
| -20% | -$54.2K |
|
286
Sutro Biopharma
STRO
$89.9M
| $216K | 0.09% |
11,644
-2,168
| -16% | -$40.2K |
|
|
GTHX
287
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $216K | 0.09% |
9,832
-5,487
| -36% | -$121K |
|
288
Annovis Bio
ANVS
$44.6M
| $215K | 0.09% |
+2,518
| New | +$215K |
|
289
Annexon
ANNX
$238M
| $214K | 0.09% |
9,515
-2,656
| -22% | -$59.7K |
|
290
BridgeBio Pharma
BBIO
$10.2B
| $214K | 0.09% |
3,509
-1,393
| -28% | -$85K |
|
291
89bio
ETNB
$1.32B
| $214K | 0.09% |
11,442
+91
| +0.8% | +$1.7K |
|
292
ImmunityBio
IBRX
$2.27B
| $214K | 0.09% |
14,982
-10,868
| -42% | -$155K |
|
293
IDEAYA Biosciences
IDYA
$2.38B
| $214K | 0.09% |
+10,177
| New | +$214K |
|
294
Kymera Therapeutics
KYMR
$3.11B
| $214K | 0.09% |
+4,421
| New | +$214K |
|
295
Lexicon Pharmaceuticals
LXRX
$396M
| $214K | 0.09% |
+46,699
| New | +$214K |
|
|
MRNS
296
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $214K | 0.09% |
11,930
-10,982
| -48% | -$197K |
|
297
Adverum Biotechnologies
ADVM
$73.9M
| $213K | 0.09% |
6,079
+3,935
| +184% | +$138K |
|
298
Black Diamond Therapeutics
BDTX
$167M
| $213K | 0.09% |
17,462
+8,706
| +99% | +$106K |
|
299
Immatics
IMTX
$761M
| $213K | 0.09% |
18,350
-12,708
| -41% | -$148K |
|
300
Avidity Biosciences
RNA
$6.48B
| $213K | 0.09% |
8,613
-525
| -6% | -$13K |
|